HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Kura Oncology (NASDAQ:KURA) and maintains a $32 price target.
June 12, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Kura Oncology and maintains a $32 price target.
The Buy rating and maintained $32 price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for Kura Oncology's stock in the short term. This reaffirmation of the Buy rating can potentially boost investor confidence and lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100